Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Astrocytoma 8Glioblastoma 5Prostatic Neoplasms 4Neuroectodermal Tumors, Primitive 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 3Glioma 3Breast Neoplasms 3Recurrence 2Oligodendroglioma 2Neurocytoma 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Pituitary Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

pembrolizumab 9avelumab 9Nivolumab 8atezolizumab 4Specimen Handling 4durvalumab 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3Biopsy 3ALT-803 3talimogene laherparepvec 2fludarabine phosphate 2fludarabine 2domatinostat 2Radiosurgery 2Ipilimumab 2Cisplatin 2Carboplatin 2relatlimab 1oblimersen 1lutetium Lu 177 dotatate 1lenvatinib 1lanreotide 1daromun 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Merkel Cell × antineoplaston A10 × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡